TRIAMCINOLONE ACETONIDE tablet

Nazione: Stati Uniti

Lingua: inglese

Fonte: NLM (National Library of Medicine)

Principio attivo:

TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE - UNII:F446C597KA)

Commercializzato da:

Boehringer Ingelheim Vetmedica, Inc.

INN (Nome Internazionale):

TRIAMCINOLONE ACETONIDE

Composizione:

TRIAMCINOLONE ACETONIDE 0.5 mg

Tipo di ricetta:

PRESCRIPTION

Stato dell'autorizzazione:

New Animal Drug Application

Scheda tecnica

TRIAMCINOLONE ACETONIDE- TRIAMCINOLONE ACETONIDE TABLET
BOEHRINGER INGELHEIM VETMEDICA, INC.
----------
TRIAMCINOLONE ACETONIDE TABLETS
NADA 137-694, Approved by FDA
For oral use in dogs and cats only.
CAUTION: Federal law restricts this drug to use by or on the order of
a licensed veterinarian.
DES CRIPTION
Triamcinolone acetonide is a highly potent synthetic glucocorticoid
and anti-inflammatory agent.
Its
advantage over the older corticoids lies in its ability to achieve
equal anti-inflammatory effect with a
lower dose.
Triamcinolone has very weak sodium-retaining effects and is probably
the least
electrolyte-retaining compound of the corticosteroid group.
Triamcinolone has a plasma half-life of
approximately 300 minutes and is classified as an intermediate acting
glucocorticoid, whereas the
acetonide salt has a longer duration of action and a higher
lipid-water distribution coefficient.
INDICATIONS
Triamcinolone acetonide is a highly potent glucocorticoid effective in
the treatment of inflammation and
related disorders in dogs and cats. It is indicated in the management
and treatment of acute arthritis and
allergic and dermatologic disorders.
DOSAGE AND ADMINISTRATION
The keystone of satisfactory therapeutic management with triamcinolone
acetonide, as with other
steroids, is individualization of dosage in reference to the severity
of the disease, the anticipated
duration of steroid therapy and the animal’s threshold or tolerance
for steroid excess. The prime
objective of steroid therapy should be to achieve a satisfactory
degree of control with a minimum
effective dose.
The initial suppressive dose level of 0.5 -1.0 mg per 10 pounds of
body weight daily should be
administered until a satisfactory clinical response is obtained, a
period not to exceed 14 days. If a
satisfactory response is not obtained in 14 days, re-evaluation of the
case to confirm the original
diagnosis should be made. As soon as a satisfactory clinical response
is obtained, the daily dose should
be reduced gradually, either to termination